City page
Basel biotech and pharma directory
Basel is the historic capital of European pharma — home to Roche and Novartis global headquarters, anchor peptide and biologics CDMOs (Bachem in Bubendorf, Lonza in Visp/Basel), and a tight cohort of mid-cap therapeutic developers (Idorsia, Basilea, Noema, BioVersys, Engimmune, ARTIDIS, InSphero in Schlieren). The tri-border region with Germany and France makes it Europe's densest industrial biotech cluster, with FDA-inspected manufacturing as the default expectation across major operators.
Where does this city read strongest?
Therapeutics (7), Drug discovery (1), and Manufacturing (1). Most visible records: ARTIDIS AG, Cimeio Therapeutics AG, and Myria Biosciences AG.
Which standards and public evidence are already visible?
GMP (4), GLP (2), and ISO-13485 (1). Latest review: 24 April 2026. Review cycle: April 2026.
Why does this city matter?
This page brings visible companies and infrastructure records into one practical view of Basel.
By category
Basel by category
Jump into a category page filtered to this country only.
Full list
Basel biotech and pharma directory
12 city records currently match the active filter.
Current review cycle
ARTIDIS AG
BaselSwitzerlandDiagnostics
Basel nanomechanical diagnostics company developing the ARTIDISNet platform for accelerated cancer diagnosis through atomic force microscopy, a spin-off from the University of Basel Biozentrum.
- Lead
- Marija PlodinecChief Executive Officer and Co-Founder
- Scale
- Diagnostic platform commercialization
Current review cycle
Cimeio Therapeutics AG
BaselSwitzerlandTherapeutics
Basel shielded-cell therapy biotech developing paired cell-shielding and immunotherapy portfolios for hematologic disorders, with 46 million CHF Series A financing from Versant Ventures' Ridgeline Discovery Engine.
- Lead
- Thomas FuchsChief Executive Officer
- Scale
- Preclinical cell-therapy development
Current review cycle
Myria Biosciences AG
BaselSwitzerlandBiotech
Basel synthetic biology and AI biotech targeting undruggable conditions through AI-designed microbes that produce therapeutic molecules, an ETH Zurich Department of Biosystems Science and Engineering spin-off.
- Lead
- Steven SchmittChief Executive Officer
- Scale
- Pre-seed research operations
Current review cycle
Noema Pharma AG
BaselSwitzerlandTherapeutics
Basel clinical-stage CNS biotech developing therapies for orphan neurological disorders driven by imbalanced neuronal networks, built on ex-Roche assets and backed by Sofinnova Partners with a 103 million EUR financing.
- Lead
- Ilise LombardoChief Executive Officer
- Scale
- Clinical-stage CNS therapeutics
Current review cycle
Celonic
BaselSwitzerlandCDMO
Basel biopharmaceutical CDMO with Swiss GMP operations spanning cell-line development, process development, and biologics manufacturing.
- Lead
- Samanta CimitanChief Executive Officer
- Scale
- Commercial and development-stage biologics platform
Current review cycle
Anaveon
BaselSwitzerlandTherapeutics
Basel immunotherapy company engineering cytokine-based treatments for cancer and immune disorders from a Swiss biotech platform.
- Lead
- Dario NeriChief Executive Officer
- Scale
- Clinical-stage immunotherapy platform
Current review cycle
Alentis Therapeutics
BaselSwitzerlandTherapeutics
Basel biotech company developing Claudin-1 targeted therapeutics across fibrosis and oncology from a clinical-stage Swiss platform.
- Lead
- Mark PruzanskiChief Executive Officer
- Scale
- Clinical-stage therapeutics platform
Current review cycle
BioVersys
BaselSwitzerlandDrug discovery
Basel anti-infectives discovery anchor focused on novel antibacterial programs against multidrug-resistant pathogens.
- Lead
- Marc GitzingerChief Executive Officer
- Scale
- Swiss anti-infectives discovery hub
Current review cycle
Basilea
BaselSwitzerlandTherapeutics
Basel anti-infectives and oncology-development anchor operating a highly specialized therapeutics portfolio with partnered commercial reach.
- Lead
- David VeitchChief Executive Officer
- Scale
- Clinical and partnered specialty development
Current review cycle
Sandoz
BaselSwitzerlandManufacturing
Basel-headquartered generics and biosimilars anchor operating a global regulated manufacturing network across essential medicines.
- Lead
- Richard SaynorChief Executive Officer
- Scale
- Global regulated medicines supply
Current review cycle
Novartis
BaselSwitzerlandTherapeutics
Basel therapeutic and industrial-control anchor spanning advanced medicines, global supply governance, and large-scale pharmaceutical operations.
- Lead
- Vas NarasimhanChief Executive Officer
- Scale
- Global pharmaceutical operations
Current review cycle
Roche
BaselSwitzerlandTherapeutics
Basel therapeutics and diagnostics anchor with a global industrial network spanning pharma, biologics, and advanced diagnostics.
- Lead
- Thomas SchineckerChief Executive Officer
- Scale
- Global therapeutics and diagnostics operations
FAQ
Frequently asked questions
- Why is Basel important for biotech?
- Basel hosts two of the world's top-five pharma companies (Roche, Novartis), the largest peptide CDMO (Bachem), and a major share of biologics CDMO capacity (Lonza). The tri-border region with Germany (BASF, Boehringer) and France makes it Europe's densest industrial life sciences cluster. ETH Zurich and the University of Basel anchor the academic side.
- What companies are headquartered in Basel?
- Roche (Basel, world's second-largest pharma), Novartis (Basel, top-five global pharma), Bachem (Bubendorf, leading peptide CDMO), Lonza (Visp + Basel offices, top-three biologics CDMO), Idorsia, Basilea, Noema, BioVersys, Engimmune, ARTIDIS — all based in Basel or the immediate region. Schlieren near Zurich also hosts therapeutic developers (InSphero, Memo Therapeutics).
- What sectors are strongest in Basel biotech?
- Basel is strongest in large pharma (oncology, immunology, ophthalmology), peptide manufacturing (Bachem), biologics CDMO (Lonza), CNS therapeutics (Noema), antibody discovery, and antimicrobial therapy (BioVersys). FDA-inspected manufacturing is the default tier across major operators.
Related briefs
Briefs that mention Basel
Swiss vs German Biotech Manufacturing 2026: A Practical Comparison
How Swiss and German biologics manufacturing compare in 2026 — Lonza, Bachem, Sandoz, Octapharma, Siegfried on one side and Rentschler, Vetter, IDT Biologika, Wacker Biotech, Merck KGaA on the other — and how to choose the right country for a given programme.
Open briefSwiss Biotech & Pharma Landscape 2026: Basel, Lausanne, Zurich
A practical map of the Swiss biotech and pharma landscape in 2026 — 36 operators anchored by Roche and Novartis in Basel, peptide and oligonucleotide API at Bachem, large-scale biologics at Lonza, and Lemanic + Zurich innovation clusters.
Open briefCell & Gene Therapy Europe 2026: CAR-T, Stem Cell, ATMP, Regenerative
A practical map of the European cell and gene therapy landscape in 2026 — CAR-T and TCR-T therapeutics, stem-cell and regenerative ATMPs, tissue engineering, plus the viral-vector CDMO and tools supply chain — across 26 operators in the directory.
Open briefNext step
Read the city, then widen the view.
Use country and regional pages for wider context, and the company suggestion form for new candidate records.